Lupin Ltd.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 13.33% surge in open interest (OI) in its derivatives segment, signalling heightened market activity and evolving investor positioning. Despite a modest 0.95% gain in the stock price, Lupin’s recent trading patterns and volume dynamics suggest a complex interplay of bullish and cautious sentiment among market participants.

Lupin Ltd. is currently rated as a 'Buy' by MarketsMOJO, with this rating last updated on 16 February 2026. While the rating was adjusted on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 23 March 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Lupin Ltd. is currently rated 'Buy' by MarketsMOJO, with this rating last updated on 16 February 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 23 March 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Lupin Ltd., a key player in the Pharmaceuticals & Biotechnology sector, reached a fresh 52-week high of Rs.2375 today, underscoring robust momentum amid a mixed market environment. The stock’s recent gains reflect sustained strength supported by solid financial performance and favourable technical indicators.

Lupin Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 16 February 2026. While the rating adjustment occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 11 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling increased investor participation and potential directional bets. The stock recently hit a new 52-week high of Rs. 2,369.5, supported by rising volumes and sustained gains, reflecting a bullish sentiment among market participants.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling increased market participation and potential directional bets. The stock recently hit a new 52-week high of Rs. 2,369.5, supported by robust volume and rising investor interest, positioning it favourably against sector peers and broader market indices.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, reached a new 52-week high of Rs.2368 today, underscoring robust momentum in its stock price. This milestone reflects sustained gains over recent sessions and a notable outperformance relative to its sector and broader market indices.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, reached a fresh 52-week high today, touching Rs.2360.5. This milestone underscores the stock’s robust momentum, outperforming its sector peers and reflecting sustained financial strength over the past year.

Lupin Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 16 February 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 28 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, reached a new 52-week high of Rs.2336 today, underscoring a sustained rally that has propelled the stock well above its previous levels. This milestone reflects the company’s robust financial performance and positive market momentum amid a mixed broader market environment.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, reached a new 52-week high of Rs.2331.2 today, underscoring a sustained rally driven by robust financial performance and positive market sentiment. The stock’s recent momentum reflects its consistent gains and strong fundamentals amid a broadly positive market backdrop.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, reached a new 52-week high of Rs.2270.4 today, underscoring a sustained upward momentum. This milestone reflects the stock’s robust performance over the past year, outpacing the broader market and signalling continued strength across key financial metrics.

Lupin Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling increased market activity and potential directional bets. The stock’s latest open interest rose by 13.07% to 39,574 contracts, accompanied by robust volume and a steady price performance close to its 52-week high, reflecting growing investor confidence and evolving market positioning.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, reached a new 52-week high of Rs.2261.95 today, underscoring a notable rally and sustained momentum in its stock performance. This milestone reflects the company’s robust financial health and consistent growth trajectory over the past year.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Strong Buy to Buy as of 16 February 2026. This adjustment reflects nuanced shifts across four critical parameters: quality, valuation, financial trend, and technical indicators. While the company continues to demonstrate robust fundamentals and healthy returns, evolving market dynamics and valuation metrics have prompted a more cautious stance among analysts.